Movement disorders in paraneoplastic and autoimmune disease - PubMed (original) (raw)

Review

Movement disorders in paraneoplastic and autoimmune disease

Jessica Panzer et al. Curr Opin Neurol. 2011 Aug.

Abstract

Purpose of review: The most relevant advances in immune-mediated movement disorders are described, with emphasis on the clinical--immunological associations, novel antigens, and treatment.

Recent findings: Many movement disorders previously considered idiopathic or degenerative are now recognized as immune-mediated. Some disorders are paraneoplastic, such as anti-CRMP5-associated chorea, anti-Ma2 hypokinesis and rigidity, anti-Yo cerebellar ataxia and tremor, and anti-Hu ataxia and pesudoathetosis. Other disorders such as Sydenham's chorea, or chorea related to systemic lupus erythematosus and antiphospholipid syndrome occur in association with multiple antibodies, are not paraneoplastic, and are triggered by molecular mimicry or unknown mechanisms. Recent studies have revealed a new category of disorders that can be paraneoplastic or not, and associate with antibodies against cell-surface or synaptic proteins. They include anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis, which may cause dyskinesias, chorea, ballismus or dystonia (NMDAR antibodies), the spectrum of Stiff-person syndrome/muscle rigidity (glutamic acid decarboxylase, amphiphysin, GABA(A)-receptor-associated protein, or glycine receptor antibodies), neuromyotonia (Caspr2 antibodies), and opsoclonus--myoclonus--ataxia (unknown antigens).

Summary: Neurologists should be aware that many movement disorders are immune-mediated. Recognition of these disorders is important because it may lead to the diagnosis of an occult cancer, and a substantial number of patients, mainly those with antibodies to cell-surface or synaptic proteins, respond to immunotherapy.

PubMed Disclaimer

Cited by

Characteristics of Movement Disorders in Patients with Autoimmune GFAP Astrocytopathy.
Kimura A, Takekoshi A, Shimohata T. Kimura A, et al. Brain Sci. 2022 Mar 29;12(4):462. doi: 10.3390/brainsci12040462. Brain Sci. 2022. PMID: 35447992 Free PMC article.
Delayed onset of severe chronic pain in CASPR2 autoantibody-associated Morvan syndrome in a former UK swine abattoir worker.
Goebel A, Moore AP, Jacob A. Goebel A, et al. Pain Rep. 2018 Sep 17;3(5):e675. doi: 10.1097/PR9.0000000000000675. eCollection 2018 Sep-Oct. Pain Rep. 2018. PMID: 30534626 Free PMC article.
Neurological Complications in Patients with Systemic Lupus Erythematosus.
Shaban A, Leira EC. Shaban A, et al. Curr Neurol Neurosci Rep. 2019 Nov 26;19(12):97. doi: 10.1007/s11910-019-1012-1. Curr Neurol Neurosci Rep. 2019. PMID: 31773306 Review.
Treatment options in paraneoplastic disorders of the peripheral nervous system.
Antoine JC, Camdessanché JP. Antoine JC, et al. Curr Treat Options Neurol. 2013 Apr;15(2):210-23. doi: 10.1007/s11940-012-0210-9. Curr Treat Options Neurol. 2013. PMID: 23307613
[Therapeutic options for autoimmune encephalomyelitis].
Borisow N, Prüss H, Paul F. Borisow N, et al. Nervenarzt. 2013 Apr;84(4):461-5. doi: 10.1007/s00115-012-3608-4. Nervenarzt. 2013. PMID: 23568167 German.

References

1. Grant R, Graus F. Paraneoplastic movement disorders. Mov Disord. 2009;24:1715–1724. - PubMed
1. Darnell RB, Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol. 2006;33:270–298. - PubMed
1. Psimaras D, Carpentier AF, Rossi C. Cerebrospinal fluid study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry. 2010;81:42–45. - PubMed
2. The study describes CSF findings in PND.
1. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75:1135–1140. - PMC - PubMed
1. Samii A, Dahlen DD, Spence AM, et al. Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody. Mov Disord. 2003;18:1556–1558. - PubMed

Movement disorders in paraneoplastic and autoimmune disease - PubMed (original) (raw)